All samples·Sample analysis

Get your own pass — $199

radioligand therapy for prostate cancer OrganizationsUNIVERSITY OF WISCONSIN-MADISON

UNIVERSITY OF WISCONSIN-MADISON

Projects attributed to UNIVERSITY OF WISCONSIN-MADISON within this analysis sample.

In This Analysis

Projects

8

NIH Funding

$4.6M

Projects(8)

Project	PI	Category	Funding
Molecular Targeted Radionuclide Therapy with Tumor-Specific Vaccine to Stimulate and Expand T-cell Activation P01CA250972	MCNEEL, DOUGLAS G. (contact)	Therapeutics	$2.4M
Targeted Immunostimulatory Dual Drug Conjugates for Treating Heterogeneous Metastatic Castration Resistant Prostate Cancer R01CA315741	MEIMETIS, LABROS	Therapeutics	$650K
Harnessing the Radiochelation Chemistry of Theranostic, Rare Earth Isotopes R01EB032349	BOROS, ESZTER	Biotools	$416K
Project 3: Extending Clinical Benefit by Selective Treatment of Resistant Lesions in mCRPC 5P50CA269011-03	JERAJ, ROBERT	Infrastructure	$363K
Project 1: Priming and propagating immunity against head and neck cancer using targeted radionuclide therapy 5P50CA278595-09	MORRIS, ZACHARY SCOTT	Infrastructure	$348K
Targeted Radionuclide Therapy to Enhance the Efficacy of CAR T Cells Against Neuroblastoma 5K08CA285941-02	SODJI, QUAOVI H	Therapeutics	$319K
Combining antigen-specific vaccination with radiopharmaceutical therapy (RPT) to enhance anti-tumor immunity and efficacy F31CA305954	SHIM, DAEUN	Training	$76K
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response 3P01CA250972-05S1	WEICHERT, JAMEY P	Therapeutics	$72K

See UNIVERSITY OF WISCONSIN-MADISON’s full platform profile

Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.